Department of Cancer Medicine, Scientific Institute for Research and Treatment Foundation, National Cancer Institute, Milan, Italy.
Cancer. 2012 Dec 1;118(23):5857-66. doi: 10.1002/cncr.27624. Epub 2012 May 17.
The objective of this study was to compare the prognostic relevance of Response Evaluation Criteria in Solid Tumors (RECIST) versus Choi criteria for the assessment of response in patients with high-risk soft tissue sarcoma of the extremities or trunk wall who received preoperative chemotherapy with or without radiotherapy in a phase 3 trial.
Patients received 3 cycles of preoperative epirubicin + ifosfamide with or without radiotherapy. The diagnostic concordance between RECIST and Choi criteria and their correlation with overall survival (OS) and freedom from progression (FFP) were evaluated in a univariate Cox regression model.
In 243 of 321 eligible patients, RECIST, Choi criteria, and histology were predictive for OS and FFP. In the subgroup of 69 patients who received chemotherapy alone and were evaluable by both RECIST and Choi criteria, Choi criteria were associated significantly with OS and FFP, whereas RECIST predicted only FFP, and the pattern of agreement observed between the 2 criteria was unsatisfactory. On a dichotomous scale, comparing objective response (complete and partial responses) and lack of response (stable and progressive disease) to preoperative chemotherapy according to RECIST and Choi criteria, only Choi criteria were predictive of OS and FFP, and fair agreement between RECIST and Choi criteria was observed. When lack of progression and progression were compared (complete and partial responses + stable disease vs progressive disease), both assessment criteria were significantly predictive of OS and FFP, and there was substantial agreement between the 2 criteria.
Response to chemotherapy with or without radiotherapy was associated with a better outcome in patients with high-risk soft tissue sarcoma. Choi criteria were better predictors than RECIST in patients who received preoperative chemotherapy alone.
本研究旨在比较实体瘤反应评估标准(RECIST)与 Choi 标准在评估接受术前化疗联合或不联合放疗的高危肢体或躯干壁软组织肉瘤患者中的预后相关性,该研究为一项 3 期临床试验。
患者接受 3 个周期的术前表柔比星+异环磷酰胺,联合或不联合放疗。在单变量 Cox 回归模型中评估 RECIST 和 Choi 标准之间的诊断一致性及其与总生存期(OS)和无进展生存期(FFP)的相关性。
在 321 例符合条件的患者中,243 例患者的 RECIST、Choi 标准和组织学与 OS 和 FFP 相关。在单独接受化疗且可通过 RECIST 和 Choi 标准评估的 69 例患者亚组中,Choi 标准与 OS 和 FFP 显著相关,而 RECIST 仅预测 FFP,且这两种标准之间观察到的一致性模式不理想。在二分类尺度上,根据 RECIST 和 Choi 标准比较术前化疗的客观缓解(完全缓解和部分缓解)和无反应(稳定疾病和进展性疾病),只有 Choi 标准可预测 OS 和 FFP,且 RECIST 和 Choi 标准之间的一致性为一般。当比较无进展和进展时(完全缓解和部分缓解+稳定疾病 vs 进展性疾病),两种评估标准均显著预测 OS 和 FFP,且两种标准之间具有高度一致性。
化疗联合或不联合放疗的反应与高危软组织肉瘤患者的更好结局相关。在单独接受术前化疗的患者中,Choi 标准比 RECIST 更能预测预后。